Latest news with #ocularComplications
Yahoo
24-06-2025
- Health
- Yahoo
Rising Pediatric Allergies and Enhanced Awareness Fuel Growth
Vernal keratoconjunctivitis (VKC) is a chronic allergic eye disease that, if untreated, can cause severe ocular complications. Characterized by itching, redness, and swelling, VKC is receiving increasing attention due to growing public and healthcare awareness. Advances in biologics, immunotherapies, and targeted treatments are revolutionizing management strategies, enhancing patient outcomes. The market, segmented by drug class and region, highlights rapid growth in biologics and significant interest in North America. Drivers include increased allergic conditions, but high costs of advanced therapies present affordability challenges. Leading pharmaceutical companies like Novartis, Astellas Pharma, and Santen are spearheading innovations in this sector. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Vernal Keratoconjunctivitis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to global vernal keratoconjunctivitis market is segmented by drug class, including mast cell stabilizers, antihistamines, NSAIDs, topical corticosteroids, and emerging therapies. Vernal keratoconjunctivitis is a chronic, inflammatory allergic eye disease that can lead to severe ocular complications if left untreated. The condition is typically characterized by intense itching, redness, and swelling of the conjunctiva and cornea. With growing public and healthcare provider awareness is leading to earlier treatment and better disease management in developing introduction of biologics, immunotherapies, and targeted therapies will likely to have a transformative impact on the treatment paradigm, improving patient outcomes and enhancing disease management strategies. North America is projected to hold a significant share of the global vernal keratoconjunctivitis market, driven by advanced healthcare infrastructure, higher patient awareness, and a well-established pharmaceutical industry. In Europe, increasing focus on research and development for allergic eye diseases will continue to contribute to steady market growth. The Asia-Pacific region is also anticipated to experience rapid growth, driven by rising pollution levels and increasing environmental allergens that trigger keratoconjunctivitis treatments. How Can This Report Add Value to an Organization?Product/Innovation Strategy: The global vernal keratoconjunctivitis market is witnessing significant innovations in treatment options, especially in the areas of biologics, immunotherapies, and drug delivery systems. This report will help companies identify new product development opportunities, including oral therapies, novel eye drops, and biologic-based treatments to address the unmet needs in vernal keratoconjunctivitis Strategy: Companies seeking to stay competitive in the global vernal keratoconjunctivitis market should focus on improving the efficacy and safety profiles of current treatments, exploring combination therapies, and integrating digital health technologies to better manage patient care and track disease progression. Collaborations with research institutions and regulatory agencies will also be crucial in accelerating the development of new therapeutic solutions. Key Market Players and Competition SynopsisThe companies profiled in this report are based on thorough research and inputs from primary experts, analyzing company coverage, product portfolios, and market penetration. The leading players in the global vernal keratoconjunctivitis market include pharmaceutical companies who are actively advancing treatment options and maintaining significant shares in the market. Demand - Drivers and Limitations The global vernal keratoconjunctivitis market is witnessing rising demand due to several key drivers: Increased allergic conditions, especially in children, are driving demand for vernal keratoconjunctivitis treatments Growing public and healthcare provider awareness is leading to earlier treatment and better disease management in developing regions Limitations: Advanced therapies like biologics are expensive, leading to affordability issues, especially in low-income regions, and complicating insurance coverage Prominent Names Established in this Market Novartis AG Astellas Pharma Inc Senju Pharmaceutical Co., Ltd. Santen Pharmaceutical Co., Ltd. Key Topics Covered: Executive SummaryMarket/Product DefinitionInclusion and Exclusion1. Global Vernal Keratoconjunctivitis Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis of Vernal Keratoconjunctivitis1.2.1 By Region1.3 Market Trends1.4 Clinical Trials1.4.1 By Phase1.5 Regulatory Landscape Analysis1.5.1 Legal Requirement and Framework in U.S.1.5.2 Legal Requirement and Framework in E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Restraints1.6.4 Market Opportunities2. Global Vernal Keratoconjunctivitis Market, by Drug Class, $Million, 2023-20352.1 Mast Cell Stabilizers2.2 Antihistamines2.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)2.4 Topical Corticosteroids2.5 Others3. Global Vernal Keratoconjunctivitis Market, by Region, $Million, 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Vernal Keratoconjunctivitis Market (by Country)3.1.3.1.1 U.S.3.1.3.1.2 Canada3.2 Europe3.2.1 Key Findings3.2.2 Market Dynamics3.2.3 Market Sizing and Forecast3.2.3.1 Europe Vernal Keratoconjunctivitis Market (by Country)3.2.3.1.1 Germany3.2.3.1.2 France3.2.3.1.3 Italy3.2.3.1.4 U.K.3.2.3.1.5 Rest-of-Europe3.3 Asia-Pacific3.3.1 Key Findings3.3.2 Market Dynamics3.3.3 Market Sizing and Forecast3.3.3.1 Asia-Pacific Vernal Keratoconjunctivitis Market (by Country)3.3.3.1.1 Japan3.3.3.1.2 Rest-of-Asia-Pacific3.4 Rest-of-the-World3.4.1 Key Findings3.4.2 Market Dynamics3.4.3 Market Sizing and Forecast4. Global Vernal Keratoconjunctivitis Market Competitive Benchmarking and Company Profiles4.1 Competitive Landscape4.1.1 Key Strategies and Developments by Company4.1.1.1 Funding Activities4.1.1.2 Mergers and Acquisitions4.1.1.3 Regulatory Approvals4.1.1.4 Partnerships, Collaborations and Business Expansions4.1.2 Key Developments Analysis4.2 Company Profiles4.2.1 Company Overview4.2.2 Product Portfolio4.2.3 Target Customers / End Users4.2.4 Key Personnel4.2.5 Analyst View5. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
09-06-2025
- Health
- Medscape
Rare Yet Alarming: US Study Maps Syphilitic Uveitis Trends
Between 2013 and 2024, syphilitic uveitis remained a rare but serious manifestation of syphilis in the United States, predominantly affecting men, older individuals, and patients with concurrent HIV, and frequently resulting in low vision and blindness. METHODOLOGY: Researchers analyzed data from a national clinical database to determine the incidence and prevalence of syphilitic uveitis in the United States, as well as the rates of sexually transmitted coinfections and associated ocular complications. Participants with syphilitic uveitis were identified using diagnostic codes for uveitis and positive treponemal and nontreponemal test for syphilis obtained within 1 month of a diagnosis of uveitis. Data collection included demographic information and rates of concurrent sexually transmitted infections, including HIV, gonorrhea, and chlamydia; these infections were recorded if diagnosed at the time of, or within 1 month after, a diagnosis of uveitis. Ocular complications included macular edema and low vision or blindness, identified at the time of a diagnosis of uveitis or within 6 months thereafter. TAKEAWAY: The researchers identified 161,317 cases of syphilis and 237 cases of syphilitic uveitis; from 2013 to 2024, the cumulative incidence and prevalence rates of syphilitic uveitis were 0.36 and 0.27 per 100,000 individuals, respectively, with both incidence and prevalence increasing over this period. Compared with the general population in the same database, patients with syphilitic uveitis were more likely to be men and older. HIV was the most common concurrent sexually transmitted infection, occurring in 32.49% of cases; gonorrhea and chlamydia occurred less frequently, at 4.22%. The most common complication was low vision or blindness, occurring predominantly in patients with panuveitis or posterior uveitis. IN PRACTICE: 'Our findings reinforce the need for ordering syphilis testing at uveitis presentation and the prompt initiation of intravenous antibiotic therapy thereafter to prevent irreversible ocular damage,' the researchers wrote. SOURCE: The study was led by Lucy Ruoxi Zhou, of the Drexel University College of Medicine in Philadelphia. It was published online on June 4, 2025, in the American Journal of Ophthalmology . LIMITATIONS: The reliance on electronic health record databases may have introduced coding variability and inaccuracies. The requirement for syphilis testing to occur within 1 month after a diagnosis of uveitis potentially excluded patients tested before or on the same day as their diagnosis or those experiencing diagnostic delays longer than 1 month. This study could not assess prescribed treatments and changes in clinical endpoints, including improvement in vision or resolution of macular edema after treatment. DISCLOSURES: One author received support from the Hankins and Dracopoulos Uveitis Research Funds.
